Here, we used a bottom-up proteomic approach to investigate the consequences of reduction of HDAC activity following the treatment with the HDACis Entinostat and Vorinostat or specific deletion of Hdac1 in cell lines derived from a transgenic NPM-ALK tumor mouse model. This evidence concerns the gene HDAC9 and neoplasm.